Verrica Pharmaceuticals Inc.: management transactions · United States · SEC (Form 4)

About Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc. is a U.S.-based dermatology therapeutics company listed on the NASDAQ in the United States under the ticker VRCA. Founded in 2013 and headquartered in West Chester, Pennsylvania, the company focuses on prescription treatments for skin diseases that require medical intervention. Its positioning is highly specialized, making it a niche player in medical dermatology rather than a broad-based pharmaceutical company. Verrica’s core story centers on YCANTH® (VP-102), its lead marketed product. YCANTH is a proprietary drug-device combination containing cantharidin delivered through a single-use applicator designed for precise topical dosing. The company states that YCANTH is the first and only healthcare-professional-administered treatment approved by the FDA for molluscum contagiosum in adults and pediatric patients two years of age and older. That approval gives Verrica an important commercial and regulatory foothold in a market with limited approved options. Beyond molluscum, Verrica is developing YCANTH/VP-102 for common warts, a larger dermatology segment with meaningful unmet need. The company has been advancing a global Phase 3 program in common warts with Torii Pharmaceutical, which also points to an international development and partnering strategy. Verrica is also advancing VP-315, an oncolytic peptide being evaluated for dermatologic oncology applications, including basal cell carcinoma. This pipeline broadens the company’s opportunity set beyond a single commercial product and gives it exposure to a second high-value dermatology franchise. From a competitive standpoint, Verrica occupies a focused specialty niche. Its differentiation comes from FDA-approved product status, a device-enabled delivery system, and a pipeline aimed at indications where current treatment standards are not fully satisfactory. At the same time, the company operates in a challenging small-cap biotech environment, where execution risk, manufacturing quality control, reimbursement dynamics, and commercialization efficiency can materially affect performance. Recent developments have been important. In February 2026, Verrica appointed a new Chief Commercial Officer, underscoring management’s focus on expanding YCANTH access and strengthening commercial execution. The company has also reported new clinical and regulatory progress for VP-315 and continued advancement of its common warts Phase 3 program. For investors, VRCA remains a high-risk, high-upside dermatology name whose thesis depends on commercial traction in the United States, potential international expansion, and continued pipeline validation.